BACKGROUND AND OBJECTIVE: Epidural sufentanil is widely used for intraoperative analgesia and is recognized as a safe and effective route of administration when carefully monitored and administered at the lowest effective doses. Optimizing drug dosing requires a precise understanding of its pharmacokinetics. While it is known that sufentanil concentrations in the blood decline more slowly after epidural administration compared with intravenous administration, and the flip-flop phenomenon has been observed in this context, a pharmacokinetic model accounting for this phenomenon has not yet been described. METHODS: This study aimed to develop a pharmacokinetic model of sufentanil following epidural administration, with a focus on its absorption from the epidural space. The study was performed in 23 patients, aged 30-83Â years with an American Society of Anesthesiologists (ASA) classification of 2-3, undergoing major abdominal (oncologic and non-oncologic) surgery under general anesthesia and epidural analgesia. Blood samples were collected, and sufentanil concentrations were measured at time points ensuring coverage of the absorption phase. Population analysis was performed using a full Bayesian approach implemented in Stan/Torsten programs with the "cmdstanr" and "bbr.bayes" packages in RStudio. RESULTS: The Bayesian approach helped incorporate prior information about sufentanil disposition. A two-compartment disposition model with two-compartmental absorption best described the data, featuring a fast absorption rate constant into plasma and the peripheral compartment, and a slow redistribution process from the epidural fat compartment. CONCLUSIONS: This study mechanistically describes the flip-flop pharmacokinetics of sufentanil and allows for more precise dosing of epidural sufentanil (NCT06069219).
Pharmacokinetics of Sufentanil After Epidural Administration During the Course of Extensive Abdominal Surgery.
阅读:6
作者:Bienert Agnieszka, Moor Agnieszka Borsuk-De, OkuÅska Paulina, Ber Justyna, Siluk Danuta, Waszczuk MaÅgorzata, Kusza Krzysztof, Bartkowiak Tomasz, Szrama Jakub, Kluzik Anna, Koszel Tomasz, Wiczling PaweÅ
| 期刊: | Clinical Pharmacokinetics | 影响因子: | 4.000 |
| 时间: | 2025 | 起止号: | 2025 Sep;64(9):1331-1340 |
| doi: | 10.1007/s40262-025-01543-y | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
